Severe drug-induced dermatoses

Seminars in Cutaneous Medicine and Surgery

Volumn 33, Issue 1, 2014, Pages 49-58

  Ahronowitz, Iris ^a   Fox, Lindy P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTICLE; BULLOUS PEMPHIGOID; CUTANEOUS VASCULITIS; DRUG INDUCED BULLOUS PEMPHIGOID; DRUG INDUCED CUTANEOUS VASCULITIS; DRUG INDUCED DERMATOSIS; DRUG INDUCED DISEASE; DRUG INDUCED LINEAR IGA BULLOUS DERMATOSIS; DRUG INDUCED PEMPHIGUS; DRUG INDUCED PSEUDOLYMPHOMA; ERYTHEMA NODOSUM; HUMAN; LICHEN PLANUS; LINEAR IGA BULLOUS DERMATOSIS; LUPUS LIKE SYNDROME; PEMPHIGUS; PSEUDOLYMPHOMA; PSORIASIS; PYODERMA GANGRENOSUM; SKIN DISEASE; ADVERSE DRUG REACTION; CHEMICALLY INDUCED DISORDER; LEUKOCYTOCLASTIC VASCULITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSEUDOLYMPHOMA; SKIN DISEASES; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

EID: 84906538381     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
2. Hess E. Drug-related lupus. N Engl J Med. 1988;318(22):1460-1462. doi:10.1056/NEJM198806023182209.
3. Cush JJ, Goldings EA. Drug-induced lupus: clinical spectrum and pathogenesis. Am J Med Sci. 1985;290(1):36-45.
4. Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFa agents. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2012;10(12):889-897. doi:10.1111/j.1610-0387.2012.08000.x.
5. Rubin RL. Drug-induced lupus. Toxicology. 2005;209(2):135-147.
6. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18(11):935-940. doi:10.1177/0961203309106176.
7. Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465-472. doi:10.1111/j.1365-2133.2010.10110.x.
8. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103(1):49-51.
9. Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. Dermatology. 2013;226(2):119-123. doi:10.1159/000346694.
10. Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071-1075. doi:10.1001/jamadermatol.2013.4957.
11. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357-374. doi:10.2165/11588500-000000000-00000.
12. Hillesheim PB, Bahrami S, Jeffy BG, Callen JP. Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus. Arch Dermatol. 2012;148(2):190-193. doi:10.1001/archdermatol.2011.290.
13. Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19(9):1107-1111. doi:10.1177/0961203310370349.
14. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301(1):65-70. doi:10.1007/s00403-008-0890-x.
15. Chen M, Crowson AN, Woofter M, Luca MB, Magro CM. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31(4):818-820.
16. Gibson LE, van Hale HM, Schroeter AL. Direct immunofluorescence for the study of cutaneous drug eruptions. Acta Derm Venereol. 1986;66(1):39-44.
17. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of druginduced vasculitis. Ann Pharmacother. 2002;36(1):130-147.
18. Dubost JJ, Souteyrand P, Sauvezie B. Drug-induced vasculitides. Baillières Clin Rheumatol. 1991;5(1):119-138.
19. Ayturk S, Demir MV, Yaylaci S, Tamer A. Propylthiouracil induced leukocytoclastic vasculitis: A rare manifestation. Indian J Endocrinol Metab. 2013;17(2):339-340. doi:10.4103/2230-8210.109665.
20. Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70(1):12-17.
21. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol. 2008;20(1):35-39. doi:10.1097/BOR.0b013e3282f1331f.
22. Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between drug-induced and spontaneous forms. Br J Dermatol. 2013;169(5):1041-1048. doi:10.1111/bjd.12488.
23. Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66(6):988-994. doi:10.1016/j.jaad.2011.09.018.
24. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30(2 Pt 1):187-192.
25. Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid. A spectrum of diseases. Arch Ophthalmol. 1987;105(12):1660-1663.
26. Fellner MJ. Drug-induced bullous pemphigoid. Clin Dermatol. 1993;11(4):515-520.
27. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149(1):58-62. doi:10.1001/2013.jamadermatol.376.
28. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol. 2013;31(4):391-399. doi:10.1016/j.clindermatol.2013.01.006.
29. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996;132(3):272-276.
30. Durdu M, Baba M, Seçkin D. A case of bullous pemphigoid induced by aspirin. J Am Acad Dermatol. 2011;65(2):443-444. doi:10.1016/j.jaad.2010.02.032.
31. Diab M, Coloe J, Bechtel MA. Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis. 2009;83(3):139-140.
32. Ma H-J, Hu R, Jia C-Y, Yang Y, Song L-J. Case of drug-induced bullous pemphigoid by levofloxacin. J Dermatol. 2012;39(12):1086-1087. doi:10.1111/j.1346-8138.2012.01636.x.
33. Duong TA, Buffard V, André C, et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol. 2010;62(1):161-162. doi:10.1016/j.jaad.2009.02.031.
34. Aksakal BA, Ozsoy E, Arnavut O, Ali Gürer M. Oral terbinafine-induced bullous pemphigoid. Ann Pharmacother. 2003;37(11):1625-1627.
35. Millard TP, Smith HR, Black MM, Barker JN. Bullous pemphigoid developing during systemic therapy with chloroquine. Clin Exp Dermatol. 1999;24(4):263-265.
36. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249-253. doi:10.1111/j.1468-3083.2011.04062.x.
37. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol. 1998;16(3):379-387.
38. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera LP, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol. 2013;31(4):374-381. doi:10.1016/j.clindermatol.2013.01.004.
39. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16(3):393-397.
40. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29(4):455-457. doi:10.1016/j.clindermatol.2011.01.016.
41. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. 1998;16(3):325-332.
42. Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993;29(2 Pt 1):249-255.
43. Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol. 2006;47(1):57-59.
44. Antiga E, Melani L, Cardinali C, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol. 2005;32(12):972-975.
45. Hajnsek S, Milavec-Puretic V, Nankovic S, et al. Lichen planus induced by carbamazepine: a case report. Epilepsy Behav. 2012;24(2):269-271. doi:10.1016/j. yebeh.2012.03.037.
46. Gencoglan G, Ceylan C, Kazandi AC. Linear lichenoid drug eruption induced by valsartan. Clin Exp Dermatol. 2009;34(7):e334-335. doi:10.1111/j.1365-2230.2009.03283.x.
47. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104-111.
48. Ergül B, Koçak E, Akbal E, Köklü S, Astarci HM. Pegylated interferon associated lichen planus at the injection site. Acta Gastro-Enterol Belg. 2011;74(4):591-592.
49. Sato NA, Kano Y, Shiohara T. Lichen planus occurring after influenza vaccination: report of three cases and review of the literature. Dermatology. 2010;221(4):296-299. doi:10.1159/000321191.
50. Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination. Australas J Dermatol. 1997;38(3):152-154.
51. Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis. 2005;76(1):41-45.
52. Noakes R. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. Australas J Dermatol. 2003;44(4):302-303.
53. Kurokawa I, Umehara M, Nishijima S. Lichen planus-type drug eruption resulting from ticlopidine. Int J Dermatol. 2005;44(5):436-437.
54. Günes AT, Fetil E, Ilknur T, Birgin B, Ozkan S. Naproxen-induced lichen planus: report of 55 cases. Int J Dermatol. 2006;45(6):709-712.
55. Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Derm Venereol. 2010;90(1):73-76. doi:10.2340/00015555-0758.
56. Fessa C, Lim P, Kossard S, Richards S, Peñas PF. Lichen planus-like drug eruptions due to ß-blockers: a case report and literature review. Am J Clin Dermatol. 2012;13(6):417-421. doi:10.2165/11634590-000000000-00000.
57. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1(3):159-165.
58. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthetic Dermatol. 2010;3(1):32-38.
59. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1-14.
60. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-1327. doi:10.1111/j.1365-2036.2011.04866.x.
61. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidencebased overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol. 2006;25(1):1-11.
62. Gupta AK, Sibbald RG, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol. 1997;36(5 Pt 2):858-862.
63. Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. J Dermatol. 1993;20(5):279-286.
64. Yamamoto M, Ikeda M, Kodama H, Sano S. Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol. 2008;35(11):732-736. doi:10.1111/j.1346-8138.2008.00558.x.
65. Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare variations in IL-36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol. 2013;133(7):1904-1907. doi:10.1038/jid.2013.44.
66. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918-923.
67. Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000;18(3):265-282.
68. Roujeau JC. Neutrophilic drug eruptions. Clin Dermatol. 2000;18(3):331-337.
69. Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
70. Kandula S, Burke WS, Goldfarb JN. Clindamycin-induced Sweet syndrome. J Am Acad Dermatol. 2010;62(5):898-900. doi:10.1016/j.jaad.2009.03.050.
71. Thompson DF, Montarella KE. Drug-induced Sweet's syndrome. Ann Pharmacother. 2007;41(5):802-811.
72. Paydas S, Sahin B, Zorludemir S. Sweet's syndrome accompanying leukaemia: seven cases and review of the literature. Leuk Res. 2000;24(1):83-86.
73. Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140(5):570-574.
74. Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23(4):320-327. doi:10.1111/j.1529-8019.2010.01332.x.
75. Requena L, Yus ES. Erythema nodosum. Dermatol Clin. 2008;26(4):425-438, v. doi:10.1016/j.det.2008.05.014.
76. Requena L, Requena C. Erythema nodosum. Dermatol Online J. 2002;8(1):4.
77. Papagrigoraki A, Gisondi P, Rosina P, Cannone M, Girolomoni G. Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol. 2010;20(6):773-777. doi:10.1684/ejd.2010.1116.
78. Jaimes-López N, Molina V, Arroyave JE, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Reports. 2009;3(2):20-23. doi:10.3315/jdcr.2009.1027.
79. Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55(5 Suppl):S107-S108.
80. Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47(9):953-956. doi:10.1111/j.1365-4632.2008.03662.x.
81. Gungor K, Gonen S, Kisakol G, Dikbas O, Kaya A. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29(6):575-576.
82. Hong S-B, Lee M-H. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208(4):339-341.
83. Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266-e267. doi:10.1200/JCO.2010.32.6165.
84. Dean SM, Zirwas M. A Second Case of Sunitinib-associated Pyoderma Gangrenosum. J Clin Aesthetic Dermatol. 2010;3(8):34-35.
85. Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, Santos-Briz A, Fernández-López E. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Reports. 2012;6(3):98-99. doi:10.3315/jdcr.2012.1113.
86. Kikuchi N, Hiraiwa T, Ohashi T, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22(6):804-805. doi:10.1684/ejd.2012.1849.
87. Kumaresan M, Rai R, Sekar S, Natarajan K. Ciprofloxacin induced pyoderma gangrenosum. Indian Dermatol Online J. 2011;2(2):122-124. doi:10.4103/2229-5178.86010.
88. Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111(2):259-268.
89. Pathak P, McLachlan RS. Drug-induced pseudolymphoma secondary to lamotrigine. Neurology. 1998;50(5):1509-1510.
90. Masruha MR, Marques CM, Vilanova LCP, de Seixas Alves MT, Peres MFP, Rodrigues MG. Drug induced pseudolymphoma secondary to ethosuximide. J Neurol Neurosurg Psychiatry. 2005;76(11):1610.
91. Kabashima R, Orimo H, Hino R, Nakashima D, Kabashima K, Tokura Y. CD30-positive T-cell pseudolymphoma induced by amlodipine. J Eur Acad Dermatol Venereol. 2008;22(12):1522-1524. doi:10.1111/j.1468-3083.2008.02671.x.
92. Sawada Y, Yoshiki R, Kawakami C, et al. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol. 2010;90(5):521-522. doi:10.2340/00015555-0695.
93. Kim KJ, Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. Br J Dermatol. 2002;146(5):882-884.
94. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250-257.
95. Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol.